Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

Perrigo Applies to FDA for Rx-to-OTC Switch for 49-Year-Old Progestin-Only Birth Control Pill

  • Post author:PacConAdmin
  • Post published:July 11, 2022
  • Post category:Drug Industry Daily

Perrigo is jockeying for FDA approval for what could become the first ever over-the-counter (OTC) birth control pill in the U.S. Source: Drug Industry Daily

Continue ReadingPerrigo Applies to FDA for Rx-to-OTC Switch for 49-Year-Old Progestin-Only Birth Control Pill

Novo Nordisk Touts Potential Hemophilia Treatment at London Meeting

  • Post author:PacConAdmin
  • Post published:July 11, 2022
  • Post category:Drug Industry Daily

Novo Nordisk made some headlines in London this week, presenting positive data from hemophilia therapeutics trials at the International Society of Thrombosis and Hemostasis Annual Congress. Source: Drug Industry Daily

Continue ReadingNovo Nordisk Touts Potential Hemophilia Treatment at London Meeting

FDA, Patent Office Will Work Together to Protect Low-Cost Drugs

  • Post author:PacConAdmin
  • Post published:July 8, 2022
  • Post category:Drug Industry Daily

The FDA and the U.S. Patent and Trademark Office (PTO) will be walking the thin line between preserving patents as an incentive for groundbreaking drug developments and limiting them to…

Continue ReadingFDA, Patent Office Will Work Together to Protect Low-Cost Drugs

BMS Settles Patent Dispute With Alembic Over Blockbuster Revlimid

  • Post author:PacConAdmin
  • Post published:July 8, 2022
  • Post category:Drug Industry Daily

Bristol Myers Squibb (BMS) has settled with Alembic Pharmaceuticals over allegations that Alembic’s proposed generic drug infringed on its blockbuster blood cancer drug Revlimid (lenalidomide). Source: Drug Industry Daily

Continue ReadingBMS Settles Patent Dispute With Alembic Over Blockbuster Revlimid

Use of Continuous Manufacturing Leads to Faster Approvals, FDA Study Says

  • Post author:PacConAdmin
  • Post published:July 8, 2022
  • Post category:Drug Industry Daily

The use of continuous manufacturing (CM) technology resulted in applicants getting FDA approval faster when compared to batch manufacturing products, according to an FDA audit published in the International Journal…

Continue ReadingUse of Continuous Manufacturing Leads to Faster Approvals, FDA Study Says

Republicans Seek to Slow Collins-Shaheen Insulin Price-Capping Bill

  • Post author:PacConAdmin
  • Post published:July 8, 2022
  • Post category:Drug Industry Daily

Five Republican senators have called on the Senate Finance Committee to hold hearings on a proposed bill that aims to cap the cost of insulin at $35 a month before…

Continue ReadingRepublicans Seek to Slow Collins-Shaheen Insulin Price-Capping Bill

Biogen, Eisai Gains Accelerated Approval Pathway for Antiamyloid Antibody Lecanemab

  • Post author:PacConAdmin
  • Post published:July 7, 2022
  • Post category:Drug Industry Daily

The FDA has accepted lecanemab — the potential heir to Aduhelm’s tarnished fortunes — into its Accelerated Approval pathway, giving the antiamyloid antibody a chance to put Biogen and Eisai…

Continue ReadingBiogen, Eisai Gains Accelerated Approval Pathway for Antiamyloid Antibody Lecanemab

Policy Experts: Pallone’s Bill Would Give FDA More Control Over Fast-Tracked Drugs

  • Post author:PacConAdmin
  • Post published:July 7, 2022
  • Post category:Drug Industry Daily

A Democrat-sponsored bill could help solve some of the vexing problems that plague the FDA’s accelerated approval program, allowing it to still bring important new medicines to market quickly, but…

Continue ReadingPolicy Experts: Pallone’s Bill Would Give FDA More Control Over Fast-Tracked Drugs

Senate Democrats Propose Much-Anticipated Legislation Allowing Medicare to Negotiate Drug Prices

  • Post author:PacConAdmin
  • Post published:July 7, 2022
  • Post category:Drug Industry Daily

Senate Democrats are advancing a long-awaited proposal for legislation that would allow Medicare to negotiate lower prescription drug prices. Source: Drug Industry Daily

Continue ReadingSenate Democrats Propose Much-Anticipated Legislation Allowing Medicare to Negotiate Drug Prices

FDA Revises EUA to Allow Pharmacists to Prescribe Pfizer’s Paxlovid

  • Post author:PacConAdmin
  • Post published:July 6, 2022
  • Post category:Drug Industry Daily

The FDA has revised the Emergency Use Authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir and ritonavir) to allow state-licensed pharmacists to prescribe the oral antiviral drug to COVID-19 patients. Source: Drug…

Continue ReadingFDA Revises EUA to Allow Pharmacists to Prescribe Pfizer’s Paxlovid
  • Go to the previous page
  • 1
  • …
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • …
  • 328
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.